Blurbs

Analysts Are Bullish on These Healthcare Stocks: Wave Life Sciences (WVE), Ayr Wellness (AYRWF)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Wave Life Sciences (WVEResearch Report), Ayr Wellness (AYRWFResearch Report) and Nkarta (NKTXResearch Report) with bullish sentiments.

Wave Life Sciences (WVE)

Mizuho Securities analyst Salim Syed maintained a Buy rating on Wave Life Sciences today and set a price target of $13.00. The company’s shares closed last Thursday at $4.08.

According to TipRanks.com, Syed ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -16.3% and a 33.7% success rate. Syed covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Atara Biotherapeutics, and Assembly Biosciences.

Wave Life Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $9.67.

See Insiders’ Hot Stocks on TipRanks >>

Ayr Wellness (AYRWF)

Needham analyst Matt McGinley maintained a Buy rating on Ayr Wellness today and set a price target of $7.00. The company’s shares closed last Thursday at $3.60, close to its 52-week low of $2.30.

According to TipRanks.com, McGinley is a 4-star analyst with an average return of 6.3% and a 32.4% success rate. McGinley covers the Basic Materials sector, focusing on stocks such as Ascend Wellness Holdings LLC, Green Thumb Industries, and Curaleaf Holdings.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ayr Wellness with a $10.80 average price target, representing a 191.9% upside. In a report issued on October 28, BTIG also initiated coverage with a Buy rating on the stock with a C$10.50 price target.

Nkarta (NKTX)

Needham analyst Gil Blum maintained a Buy rating on Nkarta today and set a price target of $26.00. The company’s shares closed last Thursday at $10.73.

According to TipRanks.com, Blum has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -24.6% and a 26.8% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Aeglea Biotherapeutics, and Rocket Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nkarta with a $40.00 average price target, a 284.6% upside from current levels. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $81.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on WVE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More